JPRN-jRCT2080223775
Unknown
Phase 1
A Phase I Single-Dose Study of RO7046015 in Healthy Japanese Men
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD.
- Enrollment
- 24
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy Japanese man who is 21 to 65 years of age at the time of informed consent.
- •2\. Body weight of \>45 kg and \<\=110 kg at screening. Body mass index (weight \[kg]/\[height {m}]2\) of 18 to \<\=32 kg/m2 at screening.
- •3\. Consent by partner of childbearing potential to use a contraceptive method (hormonal contraceptives, intrauterine device, barrier method \[excluding rhythm method], etc.) from 30 days before administration of the IMP until 174 days after administration.
- •4\. Written informed consent.
Exclusion Criteria
- •1\. Clinically significant illness or clinically significant surgery within 4 weeks before starting administration of the IMP.
- •2\. Participation in a clinical study and treatment with an IMP (including placebo) within 4 months (or 5 half\-lives of the other IMP, whichever is longer) before enrollment.
- •3\. Vaccination with a live or inactivated vaccine within 30 days before enrollment, or anticipated vaccination with a live or inactivated vaccine during the study period.
- •4\. Use of systemic corticosteroids or other immunomodulators within 30 days before enrollment.
- •5\. Use of prescription drugs within 14 days before enrollment. However, subjects will be permitted to use products that do not result in systemic exposure and would therefore have no effect even if they were used, such as topical antiseptics and eye\-drops.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
Single-dose study of M707102 in healthy subjectsJPRN-jRCT2071230090ishiura Tomoyuki16
Unknown
Phase 1
ONO-6950 Phase I StudyAsthmaJPRN-jRCT2080221411ONO PHARMACEUTICAL CO.,LTD.56
Unknown
Phase 1
ONO-6950 Phase 1 StudyAsthmaJPRN-jRCT2080221601ONO PHARMACEUTICAL CO.,LTD.52
Recruiting
Phase 1
Phase I study of RO7187797 in patients with Multiple myeloma.Multiple myelomaJPRN-jRCT2061220045anki Toshihiro6
Completed
Phase 1
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With ER+ and HER2- Recurrent/Metastatic Breast CancerER+ and HER2- Recurrent/Metastatic Breast CancerJPRN-jRCT2080225333Eisai Co., Ltd.72